Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: A post-hoc analysis of 5 double-blind, randomized clinical trials

BMC Psychiatry

Volumn 9, Issue , 2009, Pages

  Stauffer, Virginia ^a   Ascher Svanum, Haya ^a   Liu, Lin ^a   Ball, Tamara ^b   Conley, Robert ^a  

^a ELI LILLY AND COMPANY   (United States)

^b i3 Statprobe   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; BENZODIAZEPINE DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE; THIAZOLE DERIVATIVE;

ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; HUMAN; OUTCOME ASSESSMENT; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TREATMENT DURATION; ADOLESCENT; ADULT; AGED; FEMALE; MALE; MIDDLE AGED; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DIBENZOTHIAZEPINES; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISPERIDONE; SCHIZOPHRENIA; THIAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 65449188660     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-9-13     Document Type: Article

References (30)

1. Ascher-Svanum H Faries DE Zhu B Ernst FR Swartz MS Swanson JW Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care J Clin Psychiatry 2006, 67(3):453-460 16649833
2. Dunayevich E Ascher-Svanum H Zhao F Jacobson JG Phillips GA Dellva MA Green AI Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder J Clin Psychiatry 2007, 68(8):1163-1171 17854239
3. Lieberman JA Stroup TS McEvoy JP Swartz MS Rosenheck RA Perkins DO Keefe RS Davis SM Davis CE Lebowitz BD Severe J Hsiao JK Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N Engl J Med 2005, 353(12):1209-1223 10.1056/NEJMoa051688 16172203
4. Liu-Seifert H Adams DH Kinon BJ Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: A pooled post-hoc analysis of four atypical antipsychotic drugs BMC Med 2005, 3:21 1327673 16375765 10.1186/1741-7015-3-21
5. Kinon BJ Ascher-Svanum H Adams DH Chen L The temporal relationship between symptom change and treatment discontinuation in a pooled analysis of 4 schizophrenia trials J Clin Psychopharmacol 2008:28(5):544-549 10.1097/JCP.0b013e318185e74a 18794651
6. Kay SR Fiszbein A Opler LA The positive and negative syndrome scale (PANSS) for schizophrenia Schizophr Bull 1987, 13(2):261-276 3616518
7. Overall JE Gorham DR The Brief Psychiatric Rating Scale Psychol Rep 1962, 10:651-662
8. Davis JM Chen N Glick ID A meta-analysis of the efficacy of second-generation antipsychotics Arch Gen Psychiatry 2003, 60(6):553-564 10.1001/archpsyc.60.6.553 12796218
9. Leucht S Davis JM Engel RR Kane JM Wagenpfeil S Defining 'response' in antipsychotic drug trials: Recommendations for the use of scale-derived cutoffs Neuropsychopharmacology 2007, 32(9):1903-1910 10.1038/ sj.npp.1301325 17287825
10. Guy W Clinical Global Impression. ECDEU Assessment Manual for Psychopharmacology, revised Publication ADM 76-338. Rockville, MD, National Institute of Mental Health 1976
11. Leucht S Kane JM Kissling W Hamann J Etschel E Engel RR What does the PANSS mean? Schizophr Res 2005, 79(2-3):231-238 10.1016/ j.schres.2005.04.008 15982856
12. Nasrallah HA Dursun SM Raising the bar for treatment expectations in schizophrenia: Achieving remission as a routine goal of antipsychotic pharmacotherapy J Psychopharmacol 2006, 20(Suppl 6):3-5 10.1177/ 1359786806071221
13. Tran PV Hamilton SH Kuntz AJ Potvin JH Andersen SW Beasley C Jr Tollefson GD Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders J Clin Psychopharmacol 1997, 17(5):407-418 10.1097/00004714-199710000-00010 9315992
14. Kinon BJ Noordsy DL Liu-Seifert H Gulliver AH Ascher-Svanum H Kollack-Walker S Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning J Clin Psychopharmacol 2006, 26(5):453-461 10.1097/ 01.jcp.0000236658.16286.25 16974184
15. Kane JM Osuntokun O Kryzhanovskaya L Xu W Stauffer V Watson S Breier A A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia J Clin Psychiatry 2009, 19323965
16. Kinon BJ Lipkovich I Edwards SB Adams DH Ascher-Svanum H Siris SG A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms J Clin Psychopharmacol 2006, 26(2):157-162 10.1097/01.jcp.0000204137.82298.06 16633144
17. Breier A Berg PH Thakore JH Naber D Gattaz WF Cavazzoni P Walker DJ Roychowdhury SM Kane JM Olanzapine versus ziprasidone: Results of a 28-week double-blind study in patients with schizophrenia Am J Psychiatry 2005, 162(10):1879-1887 10.1176/appi.ajp.162.10.1879 16199834
18. Roychowdhury SM Sethuraman G Ahmed S Comparison of olanzapine to other atyptical antipsychotics in preventing relapse in patients with schizophrenia [abstract] Abstracts of the XIIth Biennial Winter Workshop on Schizophrenia: 7-13 February 2004; Davos, Switzerland. Schizophr Res 2004, 67(Suppl 1):165
19. Emsley R Rabinowitz J Medori R Time course for antipsychotic treatment response in first-episode schizophrenia Am J Psychiatry 2006, 163(4):743-745 10.1176/appi.ajp.163.4.743 16585455
20. Lehman AF Lieberman JA Dixon LB McGlashan TH Miller AL Perkins DO Kreyenbuhl J American Psychiatric Association; Steering Committee on Practice Guidelines Practice guideline for the treatment of patients with schizophrenia, second edition Am J Psychiatry 2004, 161(2 Suppl):1-56 15000267
21. Miller AL Hall CS Buchanan RW Buckley PF Chiles JA Conley RR Crismon ML Ereshefsky L Essock SM Finnerty M Marder SR Miller DD McEvoy JP Rush AJ Saeed SA Schooler NR Shon SP Stroup S Tarin-Godoy B The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update J Clin Psychiatry 2004, 65(4):500-508 15119912
22. Stauffer VL Karagianis J Sutton V Ascher-Svanum H Treuer T Silva de Lima M Ball T Poole-Hoffmann V Tohen M Number Needed to Treat (NNT) and Number Needed to Harm (NNH) in Randomized, Blinded Trials Comparing Olanzapine to Other Atypical Antipsychotics for Treatment of Schizophrenia Clinical Schizophrenia & Related Psychoses 2008, 2(2):136-146 10.3371/CSRP.2.2.3
23. Gilmer TP Dolder CR Lacro JP Folsom DP Lindamer L Garcia P Jeste DV Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia Am J Psychiatry 2004, 161(4):692-699 10.1176/appi.ajp.161.4.692 15056516
24. Nasrallah HA Lasser R Improving patient outcomes in schizophrenia: achieving remission J Psychopharmacol 2006, 20(Suppl 6):57-61 10.1177/ 1359786806071248
25. Sethuraman G Taylor CC Enerson M Dunayevich E A retrospective comparison of cumulative time spent in remission during treatment with olanzapine or risperidone among patients with schizophrenia Schizophr Res 2005, 79(2-3):337-340 10.1016/j.schres.2005.06.015 16054802
26. Andreasen NC Carpenter WT Jr Kane JM Lasser RA Marder SR Weinberger DR Remission in schizophrenia: Proposed criteria and rationale for consensus Am J Psychiatry 2005, 162(3):441-449 10.1176/ appi.ajp.162.3.441 15741458
27. Lieberman JA Phillips M Gu H Stroup S Zhang P Kong L Ji Z Koch G Hamer RM Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: A 52-week randomized trial of clozapine vs chlorpromazine Neuropsychopharmacology 2003, 28(5):995-1003 12700715
28. Beasley CM Jr Stauffer VL Liu-Seifert H Taylor CC Dunayevich E Davis JM All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: An integrated analysis J Clin Psychopharmacol 2007, 27(3):252-258 10.1097/JCP.0b013e3180582426 17502771
29. Fleischhacker WW McQuade RD Marcus RN Archibald D Swanink R Carson WH A Double-Blind, Randomized, Comparative Study of Aripiprazole and Olanzapine in the Treatment of Patients with Acute Schizophrenia Biol Psychiatry 2009, 65:510-517 10.1016/j.biopsych.2008.07.033 18986646
30. Zyprexa [package insert] Indianapolis, IN, Eli Lilly and Company 2008